FDA Encourages Rezolute to Submit Full Data for Failed Phase 3 Drug, Offering Path Forward

summarizeSummary

Rezolute announced that the FDA encouraged the company to submit comprehensive data from its sunRIZE Phase 3 trial for ersodetug, despite the trial not meeting its primary endpoint, providing a potential path forward for the congenital hyperinsulinism program.

check_boxKey Events

• FDA Meeting Outcome

  Rezolute held a Type B meeting with the FDA on March 17, 2026, regarding its ersodetug program for congenital hyperinsulinism.

• Data Submission Encouraged

  Despite the sunRIZE Phase 3 trial not meeting its primary endpoint, the FDA encouraged Rezolute to submit comprehensive study reports and analysis datasets for independent evaluation.

• Potential Path Forward

  The company believes that following the FDA's review, a determination may be made regarding the sufficiency of evidence to support a marketing application or if additional information is required.

• Timeline for Update

  Rezolute expects to provide an update on the program in the second half of 2026.

auto_awesomeAnalysis

This 8-K provides a crucial update on Rezolute's lead drug candidate, ersodetug, following the previously announced failure of its sunRIZE Phase 3 trial in December 2025. While the trial did not meet its primary endpoint, the FDA's decision to encourage the submission of comprehensive study reports and analysis datasets for independent evaluation is a significant positive development. This indicates the agency is not dismissing the program outright and is open to reviewing the company's arguments regarding confounding factors and positive secondary endpoints. This outcome offers a potential lifeline for ersodetug and mitigates some of the severe negative impact from the initial trial failure, extending the drug's development runway and providing hope for a marketing application. Investors should monitor the FDA's review process and the company's expected update in the second half of 2026.